Increased platelet reactivity in dyslipidemic patients with coronary artery disease on dual anti-platelet therapy.
P2Y12 inhibitor
dyslipidemia
high-density lipoprotein cholesterol
platelet activation
platelet function
Journal
Archives of medical science : AMS
ISSN: 1734-1922
Titre abrégé: Arch Med Sci
Pays: Poland
ID NLM: 101258257
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
22
06
2017
accepted:
09
09
2017
entrez:
31
1
2019
pubmed:
31
1
2019
medline:
31
1
2019
Statut:
ppublish
Résumé
The optimal duration of dual anti-platelet therapy (DAPT) following percutaneous coronary intervention (PCI) is still a matter of debate. Biomarkers may help to identify patients who will benefit from extended DAPT. The aim of the study was to test the interaction between lipid parameters and platelet function in patients with coronary artery disease (CAD) on DAPT. Overall, 58 patients on DAPT were prospectively included following PCI in stable CAD. Platelet markers, i.e. mean platelet volume (MPV), platelet distribution width (PDW), fraction of reticulated thrombocytes (RT) and ADP-induced multiple electrode aggregometry (MEA), as well as serum lipids, i.e. high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides (TG) and remnant cholesterol (RC), were assessed after intake of a maintenance dose of ASA and P2Y12 inhibitor. A significant inverse correlation was found for HDL-C levels and markers of platelet activation: MPV ( Within lipid parameters, only HDL-C levels are strongly associated with markers of platelet activation in CAD patients on DAPT. Accordingly, detection of dyslipidemia might indicate the need for prolongation of DAPT.
Identifiants
pubmed: 30697254
doi: 10.5114/aoms.2018.81035
pii: 34568
pmc: PMC6348363
doi:
Types de publication
Journal Article
Langues
eng
Pagination
65-71Déclaration de conflit d'intérêts
Bernhard Jäger and Kurt Huber received an unrestricted research grant from Astra Zeneca. All other co-authors report no conflicts of interest.
Références
Am J Cardiol. 1999 Nov 1;84(9):1011-7
pubmed: 10569655
J Am Coll Cardiol. 2004 Nov 16;44(10):2091-3
pubmed: 15542299
Diabetes. 2005 Aug;54(8):2430-5
pubmed: 16046311
Pathophysiol Haemost Thromb. 2006;35(3-4):270-80
pubmed: 16877876
Thromb Haemost. 2006 Dec;96(6):781-8
pubmed: 17139373
J Am Coll Cardiol. 2008 Aug 26;52(9):743-9
pubmed: 18718422
Clin Chem. 2009 May;55(5):888-94
pubmed: 19395440
Thromb Res. 2009 Nov;124(5):536-40
pubmed: 19467699
J Thromb Haemost. 2010 Jan;8(1):148-56
pubmed: 19691485
Ann Intern Med. 2009 Nov 3;151(9):622-30
pubmed: 19884623
Circulation. 2009 Nov 24;120(21):2095-104
pubmed: 19901191
Prog Lipid Res. 2012 Oct;51(4):314-24
pubmed: 22609245
Eur Heart J. 2012 Oct;33(20):2569-619
pubmed: 22922416
J Am Coll Cardiol. 2013 Jan 29;61(4):427-436
pubmed: 23265341
Platelets. 2014;25(5):328-36
pubmed: 23972004
Circ J. 2013;77(10):2432-48
pubmed: 24067275
Pharmacol Ther. 2014 Mar;141(3):358-67
pubmed: 24287311
ScientificWorldJournal. 2014 Mar 02;2014:794078
pubmed: 24723825
Lancet. 2014 Aug 16;384(9943):626-635
pubmed: 25131982
Eur Heart J. 2014 Oct 1;35(37):2541-619
pubmed: 25173339
Metabolism. 2014 Dec;63(12):1469-79
pubmed: 25242435
N Engl J Med. 2014 Dec 4;371(23):2155-66
pubmed: 25399658
Eur Heart J. 2015 Apr 1;36(13):774-6
pubmed: 25548060
N Engl J Med. 2015 May 7;372(19):1791-800
pubmed: 25773268
Eur Heart J. 2015 Jul 14;36(27):1762-71
pubmed: 25896078
Diabetes. 2015 Sep;64(9):3328-33
pubmed: 25972569
Thromb Haemost. 2015 Aug 31;114(3):459-68
pubmed: 26272640
Eur Heart J. 2016 Jan 14;37(3):267-315
pubmed: 26320110
JAMA. 2016 Apr 26;315(16):1735-49
pubmed: 27022822
Arch Med Sci. 2017 Feb 1;13(1):46-52
pubmed: 28144254
Arch Med Sci. 2017 Jun;13(4):705-710
pubmed: 28721135
Arch Med Sci. 2017 Jun;13(4):711-715
pubmed: 28721136
JAMA. 1986 Nov 28;256(20):2835-8
pubmed: 3773200
Atherosclerosis. 1996 Jul;124 Suppl:S11-20
pubmed: 8831911
Thromb Haemost. 1998 Aug;80(2):316-20
pubmed: 9716159